Figure 2.
Clinical distribution of the 51 n-irAEs that occurred in the 40 patients included in the study. aPD1 = anti-programmed cell death 1 antibodies; aPD-L1 = anti-programmed cell death ligand 1 antibodies; aCTLA-4 = anti-cytotoxic T-lymphocyte associated protein 4 antibodies; CTCAE = Common Terminology Criteria for Adverse Events; IDP = inflammatory demyelinating neuropathies; NMJ = neuromuscular junction disorders.